Destiny Pharma’s Call to Arms to Combat AMR
CEO Neil Clark and CSO Dr Bill Love from Europe’s leading anti-infectives biotech company Destiny Pharma, on how the makers and influencers of health policy could fuel a renaissance in drug development…
Novo Seeds: 2020 an exceptional year for creating and building companies
Novo Seeds had a very successful year with five investments. Also, substantial progress has been made across the 25 biotech companies in the portfolio, with 12 drug candidates now in the clinic.
Final Takeaways: Optimum’s 12th Annual Healthcare Investor Conference 2020
2021: Priorities for European Pharma & What does the investment landscape look like post Covid-19?
Our Year In Review
From surviving to thriving as 2021 takes the reins from 2020. In a year turned on its head by the pandemic, witnessing this month the unprecedented roll out of a novel coronavirus vaccine, with several more vaccines on the horizon, December has become a time of hope…
Expanding the armory of anti-viral approaches
Whilst the news is, finally, full of promising updates on vaccines, the world will need a wide range of prophylactic and therapeutic approaches to defeat the coronavirus.
